Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Array BioPharma (ARRY) PT Raised to $9 at Jefferies; Reiterates Buy
May 11, 2017 8:49 AM EDTJefferies raised its price target on Array BioPharma (NASDAQ: ARRY) to $9.00 (from $8.00) while maintaining a Buy rating. Lower 3Q reimbursement revenues of $26M from Novartis resulted in ~11% lower revenue of ~$33M (vs. ~$37M estimates).
For bini/enco in BRAFm CRC, assuming FDA... More
Array Biopharma (ARRY) Misses Q3 EPS by 4c
May 10, 2017 8:02 AM EDTArray Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $36.99 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
... More